Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis

CompletedOBSERVATIONAL
Enrollment

90,360

Participants

Timeline

Start Date

January 1, 2012

Primary Completion Date

March 31, 2019

Study Completion Date

June 1, 2020

Conditions
Rheumatoid ArthritisInflammatory Bowel DiseasePsoriasisPsoriatic ArthritisAnkylosing Spondylitis
Interventions
DRUG

TNF-α antagonists, non-TNFs, DMARD non-biologics

Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.

All Listed Sponsors
collaborator

HealthCore, Inc.

INDUSTRY

collaborator

Aetna, Inc.

INDUSTRY

collaborator

University of Alabama; Rheumatologist and Healthcare Research

UNKNOWN

collaborator

AbbVie

INDUSTRY

collaborator

Amgen

INDUSTRY

collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Kaiser Permanente

OTHER

collaborator

Harvard Pilgrim Health Care

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Momenta Pharmaceuticals, Inc.

INDUSTRY

collaborator

Pfizer

INDUSTRY

collaborator

University of Pittsburgh

OTHER

lead

Biologics & Biosimilars Collective Intelligence Consortium

OTHER